Affiliation:
1. Department of Quality Assurance, Gangamai College of Pharmacy, Nagaon, Dist. Dhule (M.S.), India.
Abstract
An accurate, precise and reproducible RP-HPLC method was developed for the simultaneous quantitative determination of Azelnidipine and Telmisartan in tablet dosage forms. Agilent (S.K) Gradient System UV Detector and C18 column with 250mm x 4.6mm i.d and 5μm particle size Acetonitrile: ph Buffer (80:20v/v) pH 3 was used as the mobile phase for the method. The detection wavelength was 237nm and flow rate was 0.9 ml/min. In the developed method, the retention time of Azelnidipine and Telmisartan were found to be 4.77 min and 11.97min. The developed method was validated according to the ICH guidelines. The linearity, precision, range, robustness was within the limits as specified by the ICH guidelines. Hence the method was found to be simple, accurate, precise, economic and reproducible. The developed method was validated according to the ICH guidelines. In this methods linearity, precision, range, robustness were observed. The method was found to be simple, accurate, precise, economic and reproducible. So the proposed methods can be used for the routine quality control analysis of AZN and TMZ in bulk drug as well as in formulations.
Subject
Pharmacology (medical),Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
Reference23 articles.
1. Walker R and Whittlesea C. Clinical Pharmacy and Therapeutics; 5 th Edn; Elsevier, 2007; 295-307.
2. Tamargo J and Ruilope LM., Investigational calcium channel blockers for the treatment of hypertension, Expert Opinion on Investigational Drug, 2016; 1-51.
3. Goodman and Gilman’s The pharmacological basis of therapeutics; 10th Edn; Medical Publishing Division, 2001; 1804.
4. Shewale VU et al., Azelnidipine: A Review on Therapeutic Role in Hypertension. Journal of Drug Delivery and Therapeutics, 2019; 9: 1002-1005. doi.org/10.22270/jddt.v9i3-s.3090.
5. Chen B, Yin Zhuang Zhang, Jian Quan Luo. Wei Zhang. Clinical use of Azelnidipine in the treatment of hypertension in Chinese patients. Therapeutics and Clinical Risk Management, 2015; 11: 309-318. doi: 10.2147/TCRM.S64288.